World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00307853
Date of registration: 27/03/2006
Primary sponsor: Shaare Zedek Medical Center
Public title: TRAUMEEL for Pain After Total Knee/Hip Arthroplasty
Scientific title: A Randomised, Double - Blind, Placebo Controlled Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Controlling Pain After Total Knee and Total Hip Arthroplasty.
Date of first enrolment: August 2008
Target sample size: 224
Recruitment status: Terminated
URL:  http://clinicaltrials.gov/show/NCT00307853
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Countries of recruitment
Israel
Contacts
Name:   Menachem Oberbaum, MD
Address: 
Telephone:
Email:
Affiliation:  Shaare Zedek Medical Center, Jerusalem, Israel
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients of either sex undergoing unilateral THAP or TKAP.

- Age over 18 years.

- Signature upon informed consent form

Exclusion Criteria:

- Participation in another clinical trial within 4 weeks prior to enrollment.

- Refused to give verbal consent to the telephone interviews

- Impossibility to be reached during the 14-17 days post operative

- Inability to comply with the study protocol for any other reason

- Previous major surgical procedure on ipsilateral leg.

- Current use of analgesics for any other reason.

- A history of chronic pain syndrome.

- Abused legal or illicit drug use.

- Hypersensitivity to botanicals of the Compositae family

- Known sensitivity to paracetamol, codeine or tramadol.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Total Knee and Total Hip Arthroplasty
Intervention(s)
Drug: Traumeel S
Other: Placebo
Other: Traumeel S
Primary Outcome(s)
Cumulative 48-hour postoperative morphine consumption as consumed by the patient via the PCA device [Time Frame: 48h]
Secondary Outcome(s)
AUC of NRS scores for days 14-17. [Time Frame: 14-17d]
Cumulative 24-hour postoperative morphine consumption as consumed by the patient via the PCA device [Time Frame: 24h]
Development of acute confusional state in the postoperative period [Time Frame: 14-17d]
ESR and hs-CPR at three and six days and six weeks [Time Frame: 6d and 3weeks]
IL-6 at three and six days [Time Frame: 3 and 6d]
Number of primary oral analgesic tablets ingested between days 14-17 [Time Frame: 14-17d]
Post operative blood loss [Time Frame: postoperative period]
Safety of post operative treatment [Time Frame: 6 weeks]
WOMAC [Time Frame: 6 weeks]
Secondary ID(s)
AP 06
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history